Pharmacotherapy for the prevention of post-ERCP pancreatitis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 17266688.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.
Medical subject headings
- Cholangiopancreatography, Endoscopic Retrograde
- Gastrointestinal Agents
- Octreotide
- Pancreatitis